Bevacizumab: Is the lower the better for glioblastoma patients in progression?

DISCUSSION: Use of bevacizumab at progression at lower than usual doses seems to give the same results as the standard dose without giving additional toxicity. PMID: 30301554 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30301554?dopt=Abstract

Source: Bulletin du Cancer - October 6, 2018 Category: Cancer & Oncology Authors: Sirven-Villaros L, Bourg V, Suissa L, Mondot L, Almairac F, Fontaine D, Paquis P, Burel-VandenBos F, Frenay M, Thomas P, Lebrun-Frenay C Tags: Bull Cancer Source Type: research